EBC - ON DEMAND
Debiut
European Bifurcation Club 2010, EBC 2010 – Budapest, Hungary
Hot topics
Drug Eluting Balloon in Bifurcations Trial : DEBIUT
Author: Pierfrancesco Agostoni MD, PhD, University Medical Centre Utrecht, The Netherlands
AIM
To assess the safety and efficacy of the DIORTM Paclitaxel Drug-Eluting Balloon in coronary bifurcations in combination with a BMS, with a specific focus on the side branch (SB) using the provisional T-stenting technique with final kissing balloons.
CONCLUSION
- The use of DEB in bifurcation PCI is feasible
- The pre-defined primary endpoint of 50% reduction in MB late loss has not been reached (due to better than expected BMS “angiographic” performance)
- There is a strong trend showing a favorable outcome combining DEB with a BMS in MB and using a DEB in SB with regards to overall bifurcation binary restenosis rate
- Concerning clinical endpoints, there is a consensual trend favoring DEB+BMS in terms of TLR and total MACE rates compared to BMS +POBA
- The use of DEB+BMS in bifurcations with only 3 months of DAPT seems safe with 0% occurrence of stent thrombosis
- The non-powered randomised comparison between all three arms shows a clear unfavorable outcome for the use of BMS+POBA in bifurcations